https://orcid.org/0000-0003-4936-3657
References
- What is gene therapy? Genetics Home Reference. Available from: https://ghr.nlm.nih.gov/primer/therapy/genetherapy. Accessed October 17, 2019.
- Dunbar CE, High KA, Joung JK, Kohn DB, Ozawa K, Sadelain M. Gene therapy comes of age. Science. 2018;359(6372):eaan4672. doi:10.1126/science.aan4672
- Naldini L. Gene therapy returns to centre stage. Nature. 2015;526:351–360. doi:10.1038/nature15818
- Liu MM, Tuo J, Chan CC. Gene therapy for ocular diseases. Br J Ophthalmol. 2011;95(5):604–612. doi:10.1136/bjo.2009.174912
- LaVito A. FDA approves Luxturna gene therapy for rare form of inherited vision loss; 2017. Available from: https://www.cnbc.com/2017/12/19/fda-approves-spark-therapeutics-luxturna-gene-therapy.html. Accessed October 18, 2019.
- Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, Phase 3 trial. Lancet. 2017;390(10097):849–860. doi:10.1016/S0140-6736(17)31868-8
- Maguire AM, Russell S, Wellman JA, et al. Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation–Associated Inherited Retinal Dystrophy. Ophthalmology. 2019;126(9):1273–1285. doi:10.1016/j.ophtha.2019.06.017
- Vital decisions: A pew internet health report pew research center. Available from: https://www.pewinternet.org/2002/05/22/vital-decisions-a-pew-internet-health-report/. Accessed October 18, 2019.
- Chen YY, Li CM, Liang JC, Tsai CC. Health Information Obtained From the Internet and Changes in Medical Decision Making: questionnaire Development and Cross-Sectional Survey. J Med Internet Res. 2018;20(2):e47. doi:10.2196/jmir.9370
- Safeer RS, Keenan J. Health Literacy: the Gap Between Physicians and Patients. Am Fam Physician. 2005;72(3):463–468.
- DeWalt DA, Berkman ND, Sheridan S, Lohr KN, Pignone MP. Literacy and Health Outcomes. J Gen Intern Med. 2004;19:1228–1239. doi:10.1111/j.1525-1497.2004.40153.x
- Gudgel D. Gene Therapy Approved to Treat Rare Cause of Vision Loss; 2017. Available from: https://www.aao.org/eye-health/news/gene-therapy-fda-approved-rare-retina-blindness. Accessed October 30, 2019.
- Gene therapy successful in treating rare retinal disorder; 2015. Available from: https://www.aoa.org/news/clinical-eye-care/diseases-and-conditions/gene-therapy-successful-in-treating-rare-retinal-disorder?sso=y. Accessed October 30, 2019.
- Voretigene neparvovec-rzyl (Luxturna). Available from: https://eyewiki.aao.org/Voretigene_neparvovec-rzyl_(Luxturna%E2%84%A2). Accessed October 30, 2019.
- Fischer A. FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss; 2017. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-novel-gene-therapy-treat-patients-rare-form-inherited-vision-loss. Accessed October 30, 2019.
- About LUXTERNA. Available from: https://luxturna.com/about-luxturna/. Accessed October 30, 2019.
- Roberts S. Therapy Approved for Rare Inherited Vision-Loss Disorders; 2017. Available from: https://www.medicinenet.com/script/main/art.asp?articlekey=209025. Accessed October 30, 2019.
- NIH-funded Study Points Way Forward for Retinal Disease Gene Therapy. Available from: https://www.nei.nih.gov/about/news-and-events/news/nih-funded-study-points-way-forward-retinal-disease-gene-therapy. 2015. Accessed November 18, 2019.
- Novartis announces landmark EU approval for one-time gene therapy Luxturna to restore vision in people with rare inherited retinal disease; 2018. Available from: https://www.novartis.com/news/media-releases/novartis-announces-landmark-eu-approval-one-time-gene-therapy-luxturna-restore-vision-people-rare-inherited-retinal-disease. Accessed October 30, 2019.
- Preidt R. FDA Approves Gene Therapy for Rare Form of Blindness; 2017. Available from: https://www.webmd.com/eye-health/news/20171219/fda-oks-gene-therapy-for-rare-form-of-blindness. Accessed October 30, 2019.
- Voretigene neparvovec. Available from: https://en.wikipedia.org/wiki/Voretigene_neparvovec. Accessed October 30, 2019.
- Charnock D, Shepperd S, Needham G, Gann R. DISCERN: an instrument for judging the quality of written consumer health information on treatment choices. J Epidemiol Community Health. 1999;53(2):105–111. doi:10.1136/jech.53.2.105
- Silberg WM, Lundberg GD, Musacchio RA. Assessing, Controlling, and Assuring the Quality of Medical Information on the Internet. JAMA. 1997;277(15):1244. doi:10.1001/jama.1997.03540390074039
- Readable. Available from: https://readable.io/. Accessed December 13, 2019.
- T’Hoen E. Direct-to-consumer advertising: for better profits or for better health? Am J Health-Syst Pharm. 1998;55(6):594–597. doi:10.1093/ajhp/55.6.594
- Dutta-Bergman M. Trusted Online Sources of Health Information: differences in Demographics, Health Beliefs, and Health-Information Orientation. J Med Internet Res. 2003;5(3):e21. doi:10.2196/jmir.5.3.e21
- Rozmovits L, Ziebland S. What do patients with prostate or breast cancer want from an Internet site? A qualitative study of information needs. Patient Educ Couns. 2004;53(1):57–64. doi:10.1016/S0738-3991(03)00116-2
- Morahan-Martin JM. How Internet Users Find, Evaluate, and Use Online Health Information: a Cross-Cultural Review. Cyberpsychol Behav. 2004;7(5):497–510. doi:10.1089/cpb.2004.7.497